MedPath

A clinical Trial of Mukhakantiprada lepa and its cream on human patients of hyperpigmentation on face

Not yet recruiting
Conditions
Other disorders of pigmentation,
Registration Number
CTRI/2019/05/019385
Lead Sponsor
Sane guruji Arogya kendra
Brief Summary

There are two groups in this study with 30 patients in each group, Group A will be treated with mukhkantiprada lepa and group B will be treated with Modified form of lepa as a cream. Patients will be selected for group through generated randomized number chart.Drugs for both group will be given for 30 days with follow up on 15th and 30th day of the trial.

Size of lesion,colour of lesion and number of patches will be recorded on first and follow up days.



Mukhkantiprada lepa ia mentioned by ahranghshr in vyanga but due to day today life style,shelf life of drugs,lack of time it ia difficult to use kela by people.As mukhkantiprada cream(novel dosage form)will be used as  alternative source of drug.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

1.Patient showing signs and symptoms of vyanga as per classical text like Niruja(painless),Mandala(round patch),Shyava(blotchy brown pigmentation) on face.

Exclusion Criteria
  • 1.Birth mark 2.Any known facial injuries with scares 3.Hormonal therapy and patient with systemic disorders.
  • 4.Patients on any other medication for the same problem during the study 5.Pregnant ladies.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Colour of lesion(patch)30 days
Secondary Outcome Measures
NameTimeMethod
1.Number of lesions(patch)2.Size of lesion(patch)

Trial Locations

Locations (1)

Sane guruji arogya kendra,hapasar pune

🇮🇳

Pune, MAHARASHTRA, India

Sane guruji arogya kendra,hapasar pune
🇮🇳Pune, MAHARASHTRA, India
Richa Arvind Agrawal
Principal investigator
8379901500
agrawalricha994@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.